Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Very Strong
Momentum
Price
Weak
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Strong
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Telephone
61.3.9826.0399
Address
Level 4 Suite 0403 650 Chapel Street South Yarra, Victoria (VIC) 3141
Description
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984, and is headquartered in South Yarra, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.34 - 1.16
Trade Value (12mth)
US$334,271.00
1 week
-3.94%
1 month
10.17%
YTD
27.45%
1 year
79.42%
All time high
3.60
EPS 3 yr Growth
180.90%
EBITDA Margin
%
Operating Cashflow
-$161m
Free Cash Flow Return
-275.90%
ROIC
-377.40%
Interest Coverage
-6.30
Quick Ratio
2.90
Shares on Issue (Fully Dilluted)
679m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
USD
Short Sell (% of issue)
1.39
Date | Announcements |
---|---|
19 February 25 |
Application for quotation of securities - OPT
×
Application for quotation of securities - OPT |
18 February 25 |
Opthea Completes COAST Final Week 52 Patient Visit
×
Opthea Completes COAST Final Week 52 Patient Visit |
17 February 25 |
Application for quotation of securities - OPT
×
Application for quotation of securities - OPT |
11 February 25 |
Application for quotation of securities - OPT
×
Application for quotation of securities - OPT |
11 February 25 |
Notification of cessation of securities - OPT
×
Notification of cessation of securities - OPT |
07 February 25 |
Opthea to Present at Oppenheimer Healthcare Conference
×
Opthea to Present at Oppenheimer Healthcare Conference |
06 February 25 |
Opthea Wet AMD Data Featured at Macula Society Meeting
×
Opthea Wet AMD Data Featured at Macula Society Meeting |
04 February 25 |
Change in substantial holding
×
Change in substantial holding |
31 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 January 25 |
Application for quotation of securities - OPT
×
Application for quotation of securities - OPT |
29 January 25 |
Opthea Investor Day
×
Opthea Investor Day |
14 January 25 |
Opthea's Corporate Presentation - Jan 2025
×
Opthea's Corporate Presentation - Jan 2025 |
08 January 25 |
Opthea to Host Investor Days in New York and Australia
×
Opthea to Host Investor Days in New York and Australia |
07 January 25 |
Opthea Announces Publication in Diabetic Macular Edema
×
Opthea Announces Publication in Diabetic Macular Edema |
24 December 24 |
Notification regarding unquoted securities - OPT
×
Notification regarding unquoted securities - OPT |
24 December 24 |
Notification of cessation of securities - OPT
×
Notification of cessation of securities - OPT |
24 December 24 |
Notification regarding unquoted securities - OPT
×
Notification regarding unquoted securities - OPT |
24 December 24 |
Application for quotation of securities - OPT
×
Application for quotation of securities - OPT |
19 December 24 |
Opthea to Present at 43rd J.P. Morgan Healthcare Conference
×
Opthea to Present at 43rd J.P. Morgan Healthcare Conference |
17 December 24 |
Change of Director's Interest Notice - JL
×
Change of Director's Interest Notice - JL |
17 December 24 |
Change of Director's Interest Notice -AT
×
Change of Director's Interest Notice -AT |
17 December 24 |
Change of Director's Interest Notice - JH
×
Change of Director's Interest Notice - JH |
17 December 24 |
Change of Director's Interest Notice - LG
×
Change of Director's Interest Notice - LG |
17 December 24 |
Change of Director's Interest Notice - QO
×
Change of Director's Interest Notice - QO |
17 December 24 |
Change of Director's Interest Notice - SO
×
Change of Director's Interest Notice - SO |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.